VDYNE Secures FDA Approval to Launch TRIVITA1 Pivotal IDE Trial for Its Transcatheter Tricuspid Valve Replacement System
VDYNE Secures FDA IDE Approval to Advance Pivotal TRIVITA1 Trial for Transcatheter Tricuspid Valve Replacement System VDYNE, Inc., a privately held medical device innovator focused on next-generation transcatheter valve therapies, has achieved a major regulatory milestone with the approval of…
SCP Health Broadens Performance Edge Model to Enhance Hospital-Based Care
SCP Health Expands Performance Edge Model to Strengthen Hospital-Based Care Hospitals across the United States are navigating an increasingly complex healthcare environment marked by workforce shortages, financial pressures, and rising administrative demands. In response to these challenges, SCP Health, a…
RefleXion Gains Expanded Medicare Coverage for SCINTIX Cancer Therapy
RefleXion Expands Medicare Reimbursement for SCINTIX Therapy Across Majority of U.S. Regions RefleXion Medical has announced a significant advancement in expanding access to its innovative SCINTIX® autonomous radiotherapy, as another Medicare Administrative Contractor (MAC), Noridian Healthcare Solutions, LLC, has approved…
Zentist Launches Dental RCM Bootcamp 6.0 in Nashville
Zentist to Host Dental RCM Bootcamp 6.0 in Nashville, Bringing Together Industry Leaders for Advanced Revenue Cycle Insights Zentist has officially announced that its highly anticipated Dental RCM Bootcamp 6.0 will take place from August 30 to September 1, 2026,…
Cencora Sets Schedule for Q2 Fiscal 2026 Earnings Announcement
Cencora to Release Second Quarter Fiscal 2026 Results on May 6, 2026 Cencora, Inc. has officially announced the date and time for the release of its financial results for the second quarter of fiscal year 2026. The company will publish…
Alpha Cognition Secures U.S. Patent for ALPHA-1062 Targeting Traumatic Brain Injury Treatment
Alpha Cognition Secures U.S. Patent for ALPHA-1062 in Traumatic Brain Injury, Expanding Pipeline Potential Alpha Cognition Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, has announced a significant milestone in its intellectual property strategy. The…
Alto Neuroscience Announces Phase 2 Topline Results for ALTO-101 and Pipeline Progress
Alto Neuroscience Shares Phase 2 Results for ALTO-101 and Refocuses Pipeline Strategy Alto Neuroscience, Inc., a clinical-stage biopharmaceutical company dedicated to developing precision medicines for neuropsychiatric disorders, has released topline findings from its Phase 2 proof-of-concept (POC) study evaluating ALTO-101.…
Premier Radiology Services Expands Capabilities with Acquisition of Global Imaging Solutions
Premier Radiology Services Acquires Global Imaging Solutions to Expand Teleradiology and Subspecialty Expertise Premier Radiology Services (Premier) has announced the acquisition of Global Imaging Solutions (GLOBIS), a well-established teleradiology provider known for delivering subspecialty imaging interpretations to outpatient imaging centers…
FORE Biotherapeutics’ Plixorafenib Granted Breakthrough Therapy Designation
FORE Biotherapeutics Secures Breakthrough Therapy Designation for Plixorafenib in High-Grade Glioma FORE Biotherapeutics, a clinical-stage company focused on developing precision oncology therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its…
Shionogi Completes Global Acquisition of RADICAVA Rights
Shionogi Strengthens Rare Disease Portfolio with Full Acquisition of RADICAVA (Edaravone) Shionogi & Co., Ltd. has officially completed the acquisition of all rights to RADICAVA (edaravone), marking a major milestone in the company’s strategic expansion into rare diseases. The transition…
Frontier Medicines Signs Exclusive Licensing Deal with LG Chem for First-in-Class p53 Y220C Activator FMC-220
Frontier Medicines and LG Chem Forge Strategic Global Partnership for First-in-Class p53 Y220C Activator FMC-220 Frontier Medicines Corporation has entered into a landmark exclusive licensing agreement with LG Chem, Ltd. for its novel oncology candidate FMC-220, a first-in-class covalent activator…
Mosaic Therapeutics appoints Dr Vince O’Neill, MD, as Head of R&D
Mosaic Therapeutics Strengthens Leadership with Appointment of Dr. Vince O’Neill as Head of R&D Mosaic Therapeutics, a clinical-stage oncology company focused on developing next-generation combination therapies, has announced the appointment of Dr. Vince O’Neill, MD, as its new Head of…